With increased impact from the pandemic, pharma and biotech companies are under pressure to deliver results and adapt to new business realities with a fresh approach to PPM. Covid-19 and its aftermath have brought into focus the need to prioritize better and deliver results under increased budget constraints. Project selection and portfolio valuation are crucial tools for PPM managers to understand their competitive advantage, core portfolio values and market forecasts, and to align with their strategic corporate objectives.

This marcus evans unique conference will discuss how you can articulate your priorities better in a COVID-19 environment, and how to overcome increased reporting overload and drive a positive impact in your portfolio strategy. We will explore strategic modeling in times of uncertainty, and how to align R&D and Commercial with an integrated data strategy that takes advantage of AI and machine learning opportunities. By attending this event, you will learn how to do efficient scenario prediction to achieve the right risk-benefit balance in your portfolio, and how in the long run, you can adapt to the new normal with resilient portfolio performance informed by sound-decision making.